Related Experiment Video
Updated: Aug 14, 2026
08:40
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
Dendritic cell-based vaccines in patients with hematological malignancies
W Brugger1, A Schneider, T Schammann
1University of Tübingen, Medical Center, Dept. of Hematology, Oncology, Immunology, and Rheumatology, Otfried-Müller Str. 10, 72076 Tübingen, Germany. wolfram.brugger@med.uni-tuebingen.de
Annals of the New York Academy of Sciences
|July 19, 2001
Summary
MUC1 protein is found on acute myeloid leukemia (AML) blasts. Researchers developed MUC1-specific T-cells that effectively target and destroy AML cells, suggesting MUC1 as a potential target for cancer immunotherapy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- The epithelial mucin MUC1 is frequently overexpressed in various cancers.
- MUC1 expression has been observed in some hematological malignancies like B-cell lymphomas and multiple myelomas.
- This study investigates MUC1 expression in primary acute myeloid leukemia (AML) blasts.
Purpose of the Study:
- To determine the presence and presentation of MUC1-derived peptides on primary AML blasts.
- To generate and evaluate MUC1-specific cytotoxic T-lymphocytes (CTLs) for potential AML immunotherapy.
Main Methods:
- Primary AML blasts from patients were analyzed for MUC1 and HLA-A2 expression.
- MUC1-specific CTLs were generated in vitro using peptide-pulsed dendritic cells from HLA-A2+ donors.
- CTL-mediated lysis of AML blasts was assessed, and specificity was confirmed via cold target inhibition assays.
Main Results:
- MUC1 was found to be expressed on primary AML blasts.
- Generated MUC1-specific CTLs effectively lysed primary AML blasts that expressed both MUC1 and HLA-A2.
- The cytotoxic activity of the CTLs against AML blasts was confirmed to be specific.
Conclusions:
- MUC1-derived peptides function as tumor antigens in AML.
- MUC1 represents a promising target for developing novel immunotherapeutic strategies against AML.
Related Concept Videos
01:40Cell-mediated Immune Responses
Overview
01:51Vaccinations
Overview
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...